INTRODUCTION
Drug-induced liver injury is an important concern in public health. In addition, it is one of the most common adverse events that cause lack of drug approval, drug withdrawals, and post-marketing regulatory decisions despite its low frequency in the general population. Nowadays, this adverse reaction is an important challenge during clinical phases in drug development. Hepatotoxicity is considered a multifactorial pathology dependent on host, drug and environmental aspects. This aspect combined with the wide range of clinical presentation associated with DILI, makes it difficult to characterize specific factors that play a role in DILI development. For this reason, the current study approach takes into consideration that both drug properties and host factors could modulate different features in DILI. Identifying specific parameters within these groups that could potentially have a modulatory role in DILI may help to understand the underlying mechanism(s) in DILI. In addition, the detection of such parameters could help prevent a fatal outcome for patients with this pathology. Based on previous observations, drug properties such as hepatic metabolism and lipophilicity may play an important role in delayed onset, liver injury pattern and DILI severity. Furthermore, these properties are likely to be modulated by host factors.